DR LINDEN: I think that what a woman sometimes wants to hear is “Gee, you can have the bisphosphonate instead of the chemotherapy.” And I feel like that’s really not accurate. And I think that’s selling some false hope. We’re now going to be looking at a placebo-controlled trial with denosumab. And I encourage people to enter that based on all the same interest and hypotheses — but I have equipoise about offering that trial, that’s a placebo-controlled trial, and I don’t think you — if I believe that the bisphosphonates were going to offer an advantage, we wouldn’t have opened that trial.
DR LOVE: Bill?
DR GRADISHAR: We haven’t routinely done it. The NCCN guidelines really haven’t changed to suggest that that should be a standard of care. It is a question that’s posed to us by patients — less so than it was before, but still asked. And we haven't routinely done it.
DR LOVE: Dan?
DR HAYES: I also don’t put people on it if there’s no osteoporotic or osteopenic indication and neither does anyone in my institution. We practice as a team.